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Loss-of-Function Mutations in CAST
Cause Peeling Skin, Leukonychia,
Acral Punctate Keratoses, Cheilitis, and Knuckle Pads
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Calpastatin is an endogenous specific inhibitor of calpain, a calcium-dependent cysteine protease. Here we show that loss-of-function
mutations in calpastatin (CAST) are the genetic causes of an autosomal-recessive condition characterized by generalized peeling skin,
leukonychia, acral punctate keratoses, cheilitis, and knuckle pads, which we propose to be given the acronym PLACK syndrome. In
affected individuals with PLACK syndrome from three families of different ethnicities, we identified homozygous mutations
(c.607dup, c.424A>T, and c.1750delG) in CAST, all of which were predicted to encode truncated proteins (p.Ile203Asnfs*8, p.Lys142*
, and p.Val584Trpfs*37). Immunohistochemistry shows that staining of calpastatin is reduced in skin from affected individuals. Trans-
mission electronmicroscopy revealed widening of intercellular spaces with chromatin condensation andmargination in the upper stra-
tum spinosum in lesional skin, suggesting impaired intercellular adhesion as well as keratinocyte apoptosis. A significant increase of
apoptotic keratinocytes was also observed in TUNEL assays. In vitro studies utilizing siRNA-mediated CAST knockdown revealed a
role for calpastatin in keratinocyte adhesion. In summary, we describe PLACK syndrome, as a clinical entity of defective epidermal adhe-
sion, caused by loss-of-function mutations in CAST.Peeling skin syndrome (PSS) is characterized by continuous
shedding of the stratum corneum of the epidermis with
onset from birth or infancy and lasting throughout life.1
Skin peeling can be accompanied by erythema, vesicular
lesions, or other ectodermal features including fragile
hair and nail abnormalities.2 PSS can be divided into two
clinical forms: acral PSS (APSS [MIM 609796]) and general-
ized PSS (GPSS [MIM 270300]). APSS involves the palmar,
plantar, and dorsal surfaces of hands and feet and can be
associated with mutations in transglutaminase 5 (TGM5
[MIM 603805]).3 In addition, mutations in the gene encod-
ing for the cysteine protease inhibitor cystatin A (CSTA
[MIM 184600]) have recently been associated with auto-
somal-recessive exfoliative ichthyosis (MIM 607936) and
also APSS.4,5 Individuals with inflammatory GPSS associ-
ated with mutations in corneodesmosin (CDSN [MIM
602593]) can also present with severe pruritus, food al-
lergies, and repeated episodes of angioedema, urticaria,
and asthma.6 A similar entity termed SAM syndrome (se-
vere dermatitis, multiple allergies, and metabolic wasting
[MIM 615508]), which is caused by desmoglein 1 (DSG1
[MIM 125670]) deficiency, shares clinical features with
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encoding N-acetylgalactosamine-4-O-sulfotransferase, in
a large consanguineous family with non-inflammatory
GPSS.8 However, the genetic basis of a number of PSS cases
is still unresolved.9,10
Here we show that homozygous loss-of-function (LOF)
mutations in CAST (MIM 114090) underlie autosomal-
recessive generalized PSS with leukonychia, acral punctate
keratoses, cheilitis, and knuckle pads.We propose this clin-
ical entity to be given the acronym PLACK syndrome. Via
exome sequencing and Sanger sequencing we demonstrate
that distinct homozygous LOF CAST mutations segregate
with the disorder in all three families with PLACK syn-
drome. CAST encodes calpastatin, an endogenous protease
inhibitor. Our findings emphasize the important role of
the protease-inhibitor balance in epidermal homeostasis.
We ascertained a 28-year-old Chinese female (individual
1, V-3 in Figure 1A) affected with PLACK syndrome who
was born to second-cousin parents (Figure 1A). She was
found to have trauma-induced recurrent blistering pro-
minently on the extremities since infancy, which was
worse in summer. In winter, asymptomatic skin peeling
was more prominent, either spontaneously or after the4, China; 2Beijing Key Laboratory of Molecular Diagnosis on Dermatoses,
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Figure 1. Clinical Findings of PLACK Syndrome
(A) Family pedigree of individual 1. The arrow indicates individual 1 (V-3).
(B) Individual 1 showed clinical features of generalized skin peeling, cheilitis, plantar keratoses on weight-bearing areas, blistering,
leukonychia, and knuckle pads with multiple hyperkeratotic micropapules.
(C) Histopathology of skin biopsy from lower extremities of individual 1 demonstrated intraepidermal clefting with irregular acanthol-
ysis (hematoxylin-eosin staining; scale bar represents 50 mm).
(D) Similar clinical features were found in individual 2, including skin peeling, cheilitis, punctate keratoses of the soles, leukonychia, and
knuckle pads with hyperkeratotic micropapules.remission of blistering, leaving underlying erythema. The
blistering improved and was confined to distal extremities
after puberty, and skin peeling progressed to involve nearly
the entire body. She had mild pruritus and no history of
atopic eczema, food allergy, allergic rhinitis, or asthma.
Physical examination revealed generalized dry, scaly skin
with superficial exfoliation and underlying erythema
(Figure 1B). Cheilitis with dry, shedding scales was ob-
served (Figure 1B). Several blisters were noted on her wrists
and soles. Punctate palmoplantar keratoderma was seen,
which coalesced into focal keratoderma predominately
on the weight-bearing areas (Figure 1B). Knuckle pads
with multiple hyperkeratotic micropapules were also
found involving all the interphalangeal joints. Leukony-
chia affected the proximal half of the nails with mild distal
onycholysis (Figure 1B). No other systemic abnormalities
were identified. Serum total IgE level and blood eosinophil
count were within normal range. Histological examination
of a biopsy from the scaly skin of her leg showed hyperker-The Ameatosis, acanthosis, and intraepidermal clefting with irreg-
ular acantholysis (Figure 1C).
We also investigated an affected Nepalese female (indi-
vidual 2) from non-consanguineous parents who presented
to dermatologists at age 3 with a 2-year history of painful le-
sions on the palms and soles. Clinical examination revealed
punctate keratoses on the palms, extending onto the flexor
aspect of the wrists and soles, plaques with hyperkeratotic
micropapules over the interphalangeal joints, cheilitis of
the upper lip, angular cheilitis, subtle telangiectasia on
the cheeks, follicular hyperkeratosis on the extensor sur-
face of the knees, and leukonychia of 70%–100% of the
nails (Figures 1D and S1). At review at age 4, peeling areas
had developed on the distal limbs including the extensor
surface of the knees and elbows (Figure 1D). No history of
atopic eczema, hay fever, or asthmawas recorded and serum
total IgE and eosinophil count were normal.
An additional family with known consanguinity, previ-
ously reported as having a recessive form of pachyonychiarican Journal of Human Genetics 96, 440–447, March 5, 2015 441
Figure 2. Homozygous Mutations in CAST and Its Expression and Localization in the Skin
(A) Sequence chromatograms showing homozygous mutations c.607dup, c.424A>T, and c.1750delG in the affected individuals. Arrows
indicate the position of the mutation.
(B) Homozygous frameshift mutation c.607dup-mediated mRNA decay of calpastatin in individual 1 is demonstrated by qRT-PCR
compared to the normal control. The error bar represents the SEM.
(C) Immunohistochemistry shows absent calpastatin staining in individual 1 (right) compared to normal staining throughout the
epidermis in the control (left). The scale bars represent 50 mm.congenita, was also enrolled in this study.11 In brief, both
affected European male siblings (individuals 3 and 4,
now ages 54 and 58 years old) give a history of blistering
and peeling of skin from the age of about 3 months on
the hands, feet, knuckles, elbows, and knees. Skin fragility
is induced by minor trauma and heat and continues to be
the greatest problem for these individuals. Both individ-
uals also have leukonychia, leukokeratosis, angular cheili-
tis, papules on the extensor surface of the fingers and
toes, and punctate palmar keratoses and a plantar kerato-
derma, described in more detail by Haber and Rose.11
We collected blood and saliva samples from the three
families after obtaining informed consent. This project
was approved by the Clinical Research Ethics Committee
of the Peking University First Hospital, East London and
City Health Authority Research Ethics Committee, and
the Western Institutional Review Board, which all comply
with all principles of the Helsinki Accord. After exclusion
of pathogenic mutations in TGM5, CSTA, CDSN, and
CHST8 by Sanger sequencing, we performed exome
sequencing in individual 1 using 3 mg of genomic DNA.
Exome capture was performed with the NimbleGen
SeqCap EZ Library (Roche) for enrichment and then442 The American Journal of Human Genetics 96, 440–447, March 5sequenced on an Illumina HiSeq2000 according to the
manufacturer’s protocols. Variants were filtered against
dbSNP137, the 1000 Genomes Project, HapMap8, and
BGI internal databases, as described in our previous
study. Because her parents were consanguineous, we
focused on homozygous variants to identify the underly-
ing defective gene. Among all the 148 variants fulfilling
these criteria, only 15 variants lay in coding exons or
splicing boundaries and were predicted to be ‘‘not toler-
ated’’ by SIFT.12 These included a one-nucleotide duplica-
tion in CAST that was predicted to lead to a frameshift
and truncation of the protein. By Sanger sequencing
(primers are listed in Table S1), we confirmed that this
mutation, c.607dup (p.Ile203Asnfs*8; RefSeq accession
numbers NM_001042440.3, NP_001035905.1), was ho-
mozygous in individual 1 and heterozygous in her unaf-
fected parents, siblings, and daughters (Figures 1A and
2A). This mutation was not found in 200 ethnically
matched controls.
Exome sequencing was performed on genomic DNA
from individual 2 using the NimbleGen SeqCap EZ Library
SR (Roche) and sequenced on an Illumina HiSeq2000 ac-
cording to the manufacturer’s protocols. Further details, 2015
of analysis have been described previously.12 Analysis of
novel variants revealed a homozygous nonsense mutation
(c.424A>T [p.Lys142*]) in CAST. Sanger sequencing
showed co-segregation with the disorder in this family
(Figures 2A and S1A). Subsequent exome sequencing and
Sanger sequencing also showed a homozygous frameshift
mutation, c.1750delG (p.Val584Trpfs*37), in CAST in indi-
viduals 3 and 4, which co-segregated with the disorder in
the family (primers are listed in Table S1). All three identi-
fied mutations (including c.607dup) in CAST are absent in
dbSNP137, HapMap8, the 1000 Genomes Project database,
the National Heart, Lung, and Blood Institute Exome
Sequencing Project (ESP) Exome Variant Server, and the
BGI internal database, highly suggestive of the pathoge-
nicity of these mutations based on their extreme rarity.
All three mutations identified in CAST are predicted to
encode truncated proteins and lead to a loss of function.
To investigate the consequences of homozygosity for
the c.607dup mutation in vivo, we examined the mRNA
expression of CAST in the skin from individual 1 by using
quantitative real-time PCR (qRT-PCR) (primers are listed in
Table S2). The level of CAST transcription was determined
on the basis of the comparative cycle threshold (2DDCt)
method using cDNA templates generated from a corre-
sponding area of the skin from a gender- and age-matched
healthy control as the calibrator. In contrast to the control,
we could detect only trace expression of CAST mRNA in
individual 1, probably due to mechanisms of nonsense-
mediated mRNA decay (Figure 2B). Immunohistochemical
staining was subsequently performed with a calpastatin
antibody (catalog number: sc-20779, Santa Cruz) in
paraffin-embedded sections from the pretibial skin lesion
of individual 1. A similar analysis was performed on
paraffin-embedded sections taken from xerotic left thigh
skin of individual 2, but using immunofluorescence.
Consistent with the predicted effect of the two mutations
and the results of the qRT-PCR analysis of the c.607dup
mutation, calpastatin staining was absent or reduced in
the skin from both individuals, whereas in the normal
control skin, calpastatin is localized throughout the
epidermis and has a cytoplasmic localization (Figures 2C
and S2). No skin biopsy material was available from indi-
viduals 3 or 4.
Calpastatin is a specific endogenous protease inhibitor of
calpains (m-calpain and m-calpain). Calpains are intracel-
lular cysteine proteases that require calcium or epidermal
growth factor for their catalytic activity.13 In skin, calpains
have been reported as being involved in a range of cellular
processes, including keratinocyte growth, migration, and
cell cycle regulation.14 These processes are particularly im-
portant in epidermal terminal differentiation, character-
ized by expression of specific structural proteins. Immuno-
histochemical staining of lesional skin sections from
individual 1 revealed a slight upregulation of loricrin (anti-
body catalog number ab24722, Abcam), keratin 1 (anti-
body catalog number ab24643, Abcam), and keratin 10
(antibody catalog number ab76318, Abcam) compared toThe Amecontrol (Figure S3). The increased labeling of these
proteins might be a compensatory mechanism for epi-
dermal barrier disruption.15 In contrast, the staining of
filaggrin in the epidermis of individual 1 (antibody catalog
number ab81468, Abcam) and in the epidermis of indi-
vidual 2 (antibody catalog number NCL-Filaggrin, Leica
Biosystems), as well as the staining of the tight junc-
tion component claudin-116 (antibody catalog number
13255, Cell Signaling Technology) in the epidermis of in-
dividual 1 was indistinguishable from control (data not
shown).
Because increased activity of calpains can induce
apoptosis,17 in situ apoptotic examination of keratinocytes
in the lesional skin biopsy from individual 1 was per-
formed by a TUNEL assay (In Situ Cell Death Detection
Kit, Roche). Skin sections from an unrelated healthy sub-
ject were used as a control. Images above the stratum ba-
sale were taken randomly with a fluorescence microscope
(IX71, Olympus), with the same settings for both control
and individual skin sections. Total cells and apoptotic cells
(with fluorescent nuclei) in five random high-power fields
(4003) were counted. The number of apoptotic cells in the
imaged fields was significantly increased in lesional skin
compared to normal control (Figures 3A and 3B). Ultra-
structural analysis of lesional skin sections from individual
1 was performed by transmission electron microscopy
(TEM), which showed expanded intercellular spaces
(Figure 3D), apoptotic chromatin condensation, and
margination (Figure 3E), supporting the results of the
TUNEL assay.
To determine the functional consequences of CAST
LOF mutations in vitro, we performed siRNA-mediated
knockdown (KD) of CAST by using a specific siRNA pool
(ON-TARGETplus Human CAST siRNA-SMARTpool, GE
Healthcare Dharmacon) in the immortalized keratinocyte
cell line, HaCaT. Non-targeting pool siRNA (ON-TARGET-
plus Non-targeting Pool, GE Healthcare Dharmacon) was
used as a control. Immunocytochemistry of HaCaT cell
monolayers treated with CAST siRNA and analysis of total
protein lysates by immunoblotting showed robust CAST
knockdown (Figures 4A–4C).
We then used an in vitro mechanical-induced stress
assay to investigate the role of calpastatin in keratinocyte
adhesion in CAST siRNA-treated cells (CAST KD cells)
and NTP siRNA-treated cells (NTP cells). For this we have
used the Flexcell FX-4000 Tension System (Flexcell), which
uses vacuum pressure to apply cyclic or static strain to cells
cultured on flexible-bottomed culture plates. CAST KD
cells (mimicking the homozygous LOF mutations) and
NTP cells were subjected to mechanical stretch at a fre-
quency of 5 Hz (five cycles of stretch and relaxation per
second) and an elongation of amplitude ranging from
10% to 14% (increase in diameter across the silicone
deformable membrane from 10% to 14%). Cells were
stretched for 0 hr (non-stretched) and 4 hr. Immunocyto-
chemistry with an in-house LL001 monoclonal keratin 14
antibody18 performed on siRNA-treated cells before andrican Journal of Human Genetics 96, 440–447, March 5, 2015 443
Figure 3. Increased Keratinocyte Apoptosis in Lesional Skin
(A and B) TUNEL assay demonstrated increased apoptotic level of keratinocytes in lesional skin from individual 1 (B) compared to the
control (A). The scale bars represent 50 mm.
(C and D) TEM of lesional skin from individual 1 showed expanded intercellular spaces (D, asterisks) compared to the control (C). The
scale bars represent 5 mm.
(E) At higher magnification, chromatin condensation and margination (arrows) were apparent. The scale bar represents 2 mm.after mechanical stress revealed breakage of the intercel-
lular connections in CAST KD cell monolayers, indepen-
dent of whether they had been subjected to mechanical
stress. In contrast, NTP cells presented with stretched
keratin filaments after stretching but no disruption in
intercellular adhesion prior to mechanical stress (Figures
4D–4G).
A recent study by Nassar et al. looking at CAST
overexpression in a mouse model reported significant
changes in the wound-healing process compared to normal
mice.19 CAST-overexpression mice showed a striking delay
in wound healing with reduced proliferation and re-epithe-
lialization, particularly in the early steps of the wound-heal-
ing process.19 The possible effects of CAST LOF mutations
on keratinocyte migration were assessed by performing a
scratch assay on CAST KD cell monolayers compared to
NTP cells. Because CAST KD scratch wounds appeared to
close at the same rate as NTP scratch wounds, we concluded
that cell migration in monolayers was not altered by CAST
knockdown in three independent experiments (Figure S4).
After observations in CAST LOF skin and our in vitro
studies indicating a key role for calpastatin in keratinocyte
adhesion, we examined desmosomal protein abundance.
Immunofluorescence with an antibody targeting desmo-
plakin (DSP; 11-5F mouse monoclonal, a gift from David
Garrod),20 the major protein of the desmosome, was per-
formed on frozen skin sections from individuals 1 and 2.444 The American Journal of Human Genetics 96, 440–447, March 5This showed an apparent increase in DSP abundance,
with both a plasma membrane and cytoplasmic localiza-
tion pattern compared to a specific membranous localiza-
tion pattern in control skin (Figures 4H, 4I, S3G, and
S3H). Furthermore, our in vitro studies displayed a general
trend of DSP upregulation in CAST KD cells independent
of mechanical stress when compared to NTP cells (data
not shown).
Calpain and its endogenous specific inhibitor calpasta-
tin constitute an intracellular non-lysosomal proteolytic
system ubiquitously distributed in mammal cells and
many other organisms. By catalyzing the controlled prote-
olysis of target proteins, calpains play an important role
in various cell functions, including cell proliferation,
differentiation, mobility, and cell cycle progression, as
well as cell-type-specific functions like cell fusions in myo-
blasts.13,21 Also, activation of calpains has been suggested
to trigger apoptosis by cleaving either pro-apoptotic or
anti-apoptotic proteins.22 It has been demonstrated
in vitro that increased activity of m-calpain results in
apoptosis of HaCaT cells.23 LOF mutations in CAST lead
to disinhibition of calpains, thus enhancing apoptosis of
keratinocytes, as showed in our TUNEL and TEM results.
Elevated apoptotic levels of keratinocytes can result in
skin hyperkeratosis,24,25 leading to the clinical phenotypes
of acral punctate keratoses, knuckle pads with hyperkera-
totic micropapules, and leukonychia., 2015
Figure 4. CAST Knockdown Decreases Intercellular Adhesion and Increases Desmoplakin Abundance
(A–C) HaCaTcells transfected with a pool of NTP siRNA (A) or CAST siRNA (B) were stained with an anti-calpastatin (green) antibody and
DAPI (blue) as a nuclear marker. Total protein from HaCaT cell lysates after transfection with NTP siRNA or CAST siRNA were incubated
with an anti-calpastatin antibody (C). GAPDHwas used as loading control. A significant reduction in calpastatin protein abundance can
be observed in the CAST KD cells compared to NTP cells, both by immunocytochemistry and immunoblotting.
(D–G) CAST KD (F and G) and NTP (D and E) cells were subjected to cyclic stretching for 0 hr (unstretched; D, F) and 4 hr (E, G) followed
by staining with an anti-keratin 14 antibody. Stretching of the keratin filaments can be observed after 4 hr mechanical stress in the NTP
cells (arrows) compared to unstretched monolayers. In the CAST KD cells, breakage of these filaments together with widening of the
intercellular spaces was observed independent of mechanical stress (asterisks).
(H and I) Immunohistochemistry with an anti-desmoplakin antibody on skin sections from individual 2 revealed an upregulation and
change in localization of this protein from amembranous appearance (H) to a bothmembranous and cytoplasmic appearance (I) in com-
parison to control.
The scale bars in each image represent 20 mm.Previous studies have shown that calpain could promote
focal adhesion disassembly by proteolysis of talin and focal
adhesion kinase.26,27 Our CAST KD experiments indicate
that the calpain/calpastatin system might also be critical
for intercellular adhesion. Increased calpain activity due
to LOF mutations in CASTmight lead to excessive proteol-
ysis of certain epidermal desmosomal components, which
though not extensively described in the present study,
result in impaired desmosome function characterized by
decreased resistance of the epidermis tomechanical stretchThe Ame(blistering, skin peeling, and acantholysis). This specula-
tion was further strengthened by the remarkable phe-
notypic overlap between PLACK syndrome and other
inherited disorders with desmosome deficiency, including
inflammatory GPSS,6 SAM syndrome,7 and Netherton syn-
drome (MIM 256500), the last of which was caused by LOF
mutations in SPINK5 (MIM 605010) encoding protease in-
hibitor LEKTI,28 leading to over-degradation of CDSN and
DSG1, two major components of the desmosome.29 The
increased abundance of DSP in keratinocytes observed inrican Journal of Human Genetics 96, 440–447, March 5, 2015 445
the two affected individuals might be a compensatory
mechanism in response to desmosomal damage. Although
calpastatin was suggested to play diverse physiological
roles in neurological, musculoskeletal, and ocular sys-
tems,30 no significant related symptoms were observed in
our affected individuals. Further studies are required to
elucidate whether there is redundancy of the calpain pro-
teolytic system in these organs, explaining the lack of ab-
normalities. Notably, Cast-knockout mice, which showed
increased activity of calpains, exhibit no defect under
normal conditions31 and only slight behavioral changes
in a stressful environment.32 These phenotypic differences
indicate different physiological functions of the calpain/
calpastatin system between humans and mice.
In summary, we describe the clinical features of an auto-
somal-recessive entity termed PLACK syndrome with
generalized skin peeling, leukonychia, acral punctate kera-
toses, cheilitis, and knuckle pads, distinct from epidermol-
ysis bullosa, pachyonychia congenita, and Bart-Pumphrey
syndrome (MIM 149200), a syndrome associated with
sensorineural deafness, leukonychia, and knuckle pads.
In three families with PLACK syndrome, homozygous
LOF mutations in CASTwere identified, leading to reduced
abundance of calpastatin, the only known inhibitor of cal-
pains. Mutations of protease inhibitors can disrupt the skin
barrier, impair keratinocyte adhesion, affect cell signaling,
and cause various genetic skin conditions,4,33 such as Neth-
erton syndrome caused by mutations in SPINK528 and
Nagashima-type palmoplantar keratosis (MIM 615598)
caused by mutations in SERPINB7 (MIM 603357).34,35
Our findings expand the spectrum of these conditions
and explore new avenues for proteolytic pathways in skin.Supplemental Data
Supplemental Data include four figures and two tables and can be
found with this article online at http://dx.doi.org/10.1016/j.ajhg.
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